Annual Cash & Cash Equivalents
$101.21 M
+$33.61 M+49.72%
December 1, 2024
Summary
- As of March 4, 2025, TRDA annual cash & cash equivalents is $101.21 million, with the most recent change of +$33.61 million (+49.72%) on December 1, 2024.
- During the last 3 years, TRDA annual cash & cash equivalents has fallen by -$189.85 million (-65.23%).
- TRDA annual cash & cash equivalents is now -65.23% below its all-time high of $291.06 million, reached on December 31, 2021.
Performance
TRDA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$101.21 M
+$23.16 M+29.68%
December 1, 2024
Summary
- As of March 4, 2025, TRDA quarterly cash and cash equivalents is $101.21 million, with the most recent change of +$23.16 million (+29.68%) on December 1, 2024.
- Over the past year, TRDA quarterly cash and cash equivalents has stayed the same.
- TRDA quarterly cash and cash equivalents is now -65.23% below its all-time high of $291.06 million, reached on December 31, 2021.
Performance
TRDA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TRDA Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +49.7% | 0.0% |
3 y3 years | -65.2% | +124.1% |
5 y5 years | +500.9% | +124.1% |
TRDA Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -65.2% | +124.1% | -65.2% | +124.1% |
5 y | 5-year | -65.2% | +500.9% | -65.2% | +159.2% |
alltime | all time | -65.2% | +500.9% | -65.2% | +159.2% |
Entrada Therapeutics Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $101.21 M(+49.7%) | $101.21 M(+29.7%) |
Sep 2024 | - | $78.05 M(-57.9%) |
Jun 2024 | - | $185.25 M(+170.7%) |
Mar 2024 | - | $68.44 M(+1.2%) |
Dec 2023 | $67.60 M(+49.7%) | $67.60 M(+30.3%) |
Sep 2023 | - | $51.88 M(-34.9%) |
Jun 2023 | - | $79.74 M(-65.0%) |
Mar 2023 | - | $227.65 M(+404.1%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2022 | $45.16 M(-84.5%) | $45.16 M(-15.3%) |
Sep 2022 | - | $53.31 M(-41.3%) |
Jun 2022 | - | $90.87 M(+7.4%) |
Mar 2022 | - | $84.64 M(-70.9%) |
Dec 2021 | $291.06 M(+645.5%) | $291.06 M(+138.2%) |
Sep 2021 | - | $122.17 M(-10.8%) |
Jun 2021 | - | $136.95 M(+250.7%) |
Dec 2020 | $39.05 M(+131.8%) | $39.05 M |
Dec 2019 | $16.84 M | - |
FAQ
- What is Entrada Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Entrada Therapeutics?
- What is Entrada Therapeutics annual cash & cash equivalents year-on-year change?
- What is Entrada Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Entrada Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of TRDA is $101.21 M
What is the all time high annual cash & cash equivalents for Entrada Therapeutics?
Entrada Therapeutics all-time high annual cash & cash equivalents is $291.06 M
What is Entrada Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, TRDA annual cash & cash equivalents has changed by +$33.61 M (+49.72%)
What is Entrada Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TRDA is $101.21 M
What is the all time high quarterly cash and cash equivalents for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly cash and cash equivalents is $291.06 M
What is Entrada Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, TRDA quarterly cash and cash equivalents has changed by $0.00 (0.00%)